Your session is about to expire
← Back to Search
Semaglutide for Type 2 Diabetes
Study Summary
This trial is testing a new combination therapy for type 2 diabetes, to see if it is more effective than current treatments. The study will last for 41 weeks, and participants will be given injections of either the new combination therapy or a placebo.
- Type 2 Diabetes
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2020 Phase 4 trial • 104 Patients • NCT04189848Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Has the FDA sanctioned Semaglutide for use in its treatments?
"Semaglutide has established proof of safety, but not yet evidence of efficacy - this makes it a 2 on our scale from 1 to 3."
How many individuals are enrolled in this experiment?
"This specific trial is not presently seeking out participants. It was first launched on November 29th 2021 and the most recent changes were made 11/11/2022. For those exploring other studies, there are currently 1390 trials recruiting people with type 2 diabetes mellitus and 58 that focus exclusively on Semaglutide treatment programs actively looking for patients to join their study."
What health conditions is Semaglutide typically used to treat?
"Semaglutide is typically prescribed for chronic weight management. Furthermore, it can be utilized to combat a range of other ailments when combined with exercise and an altered diet, particularly those related to bodyweight."
How many hubs are responsible for overseeing this research endeavor?
"This clinical trial is being conducted in a total of 41 distinct medical facilities. To reduce the amount of commuting needed, it is recommended to pick the centre closest to you; locations include Canoga Park, Escondido and Los Angeles."
Is this clinical trial currently welcoming participants?
"We are not currently recruiting candidates for this trial as the study was last edited on November 11th 2022. If you're looking to participate in other trials, 1390 diabetes mellitus studies and 58 Semaglutide based studies are now open for enrollment."
Have other testings of Semaglutide been implemented?
"As of now, 58 clinical trials involving Semaglutide are still in progress with a total of 27 studies at Phase 3. Although many investigations occur in Loma Linda, California, there are 3907 facilities conducting experiments concerning this medication."
Does this research trial permit the inclusion of those aged 30 and over?
"The prescribed age range for this trial is between 18 and 75; however, there are 200 trials available to minors below the age of 18 as well 1114 studies open to those who have surpassed 65 years old."
Who is eligible for enrollment in this trial?
"This investigation is looking for 495 people aged 18 to 75 who have been diagnosed with type 2 diabetes Mellitus. In addition, enrollees must be on a regimen of at least 1500 mg/day dosage of metformin or other formulae taken in the 90 days prior to screening, and their BMI must range between 25–40 kg/m^2."
Does this trial mark a precedent for further research?
"Presently, 58 ongoing trials are evaluating the effects of Semaglutide in 55 distinct nations and 772 cities. Beginning with a trial sponsored by Novo Nordisk A/S in 2018 that comprised 1387 participants who completed Phase 4 drug approval, 125 additional studies have since been finished."
Who else is applying?
What state do they live in?
How old are they?
What site did they apply to?
What portion of applicants met pre-screening criteria?
Share this study with friends
Copy Link
Messenger